Metastatic Breast Cancer Treatment
systemic anticancer therapy, and referral to supportive care and pain management—be applied. Evidence is insufficient to support the use of one BMA over another.
nV an Poznak, Catherine, et al. “Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology– Cancer Care Ontario Focused Guideline Update Summary.” Journal of Oncology Practice, 16 October 2017, DOI: 10.1200/JOP.2017.027672. Patients with breast cancer who have evidence of bone metastases should be treated with bone-modifying agents (BMAs). Options include denosumab, 120 mg subcutaneously every 4 weeks; pamidronate, 90 mg intravenously every 3 to 4 weeks; or zoledronic acid, 4 mg intravenously every 12 weeks or every 3 to 4 weeks. The analgesic effects of BMAs are modest, and they should not be used alone for bone pain. Recommend that the current standard of care for supportive care and pain management—analgesia, adjunct therapies, radiotherapy, surgery,
30
References Anello, John, et. al. “New Clinical Practice Guidelines, November 2017.” Medscape, 8 November 2017. Douglas David. “Guidelines on Bone-Modifying Agents in Metastatic Breast Cancer Updated.” Reuters Health Information, 26 October 2017, reference.medscape.com/viewarticle/888107_13. Van Poznak, Catherine, et al. “Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update Summary.” Journal of Oncology Practice, 16 October 2017, DOI: 10.1200/JOP.2017.027672.
Journal of the New York State Nurses Association, Volume 45, Number 2
